Eris Lifesciences reported an 8% YoY revenue growth to Rs 3,129 crore for FY26. While PAT jumped 73% to Rs 648 crore, aided by tax benefits, the company is seeing significant momentum in its insulin and GLP-1 segments. Investors should note the temporary OHA/cardiac segment headwinds and the regulatory delay regarding EU-GMP compliance for its sterile injectable units, which may push back CDMO revenue timelines.
Eris Lifesciences FY26 Performance Update
Consolidated Operating Revenue: Rs 3,129 crore
Consolidated PAT: Rs 648 crore
Reader Takeaway: Strong growth in the insulin franchise drives optimism, but EU-GMP regulatory delays remain a near-term compliance hurdle.
What just happened
Eris Lifesciences has released its FY26 financial results, posting a revenue of Rs 3,129 crore, representing an 8% year-on-year growth. Profit after tax (PAT) rose to Rs 648 crore, bolstered by a one-time deferred tax upside of Rs 150 crore. EBITDA margins showed improvement, climbing to 35.8% compared to 35.2% in the previous fiscal year.
Why this matters
The company is aggressively pivoting toward the 'Injectable Diabesity' segment. Its insulin franchise has seen significant market share gains, with RHI cartridge market share increasing from 8% in April 2024 to 25% by the end of FY26. The Bhopal biologics facility is now fully operational, producing over 5 million units since August 2025.
Risks to watch
Regulatory compliance is a key focus area after the company received non-compliance observations from an EU-GMP inspection in March 2026. This is likely to delay the commencement of EU CDMO revenue, originally planned for Q1 FY27. Additionally, the core Oral Anti-Diabetic (OHA) and Cardiac segments experienced temporary demand headwinds, which management aims to reverse in FY27.
Context metrics (time-bound)
- EPS: Rs 46.7 for FY26
- Cash EPS: Rs 63.2 for FY26
- Domestic Branded Formulations: ~89% of total revenue
- Adjusted RoCE: 19%
What to track next
Investors should monitor the timeline for the EU-GMP reinspection and the subsequent revenue realization from the CDMO business. Further, the commercialization of insulin cartridges in Q2 FY27 will be a critical operational milestone for the firm's growth strategy.